For Forest Laboratories Inc., the fixed-dose combination of memantine and donepezil for Alzheimer’s disease will extend the life of its lucrative Namenda franchise, while royalty payments that start five years post-launch would support development of other projects in originator Adamas Pharmaceuticals Inc.’s CNS pipeline.
On March 4, Forest announced the NDA submission for the fixed-dose combination of extended-release memantine and immediate-release donepezil, two drugs...